Edelman, a global communications and marketing company, has named Alan Maine as its new senior director, it was reported yesterday.
Maine has earlier served as head of policy and public affairs at Pfizer UK, where he was responsible for government affairs and market access policy development activity, covering both corporate and therapy area public affairs. During his time at Pfizer, Maine also worked with industry associations on campaigns, policies and initiatives relating to access to medicines. Prior to his time with Pfizer, Maine was head of government affairs at Wyeth Pharmaceuticals, later acquired by Pfizer, and has held other roles with Merck Sharpe & Dohme.
Kate Hawker, managing director for Edelman UK, said, 'We are very excited about Alan joining Edelman as he brings with him such great knowledge and insight of the complex challenges in the UK.'
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers